Abnormal QT prolongation and psychotropic drug therapy in psychiatric patients: Significance of bradycardia-dependent QT prolongation

Journal of Electrocardiology

Volumn 37, Issue 4, 2004, Pages 267-273

  Sadanaga, Tsuneaki ^a,b   Sadanaga, Fumiko ^a   Yao, Hiroshi ^a   Fujishima, Masatoshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

bradycardia; heart rate; proarrhythmia; Psychotropic drugs; QT interval; torsade de pointes

Indexed keywords

AMITRIPTYLINE; BROMPERIDOL; CARBAMAZEPINE; CHLORPROMAZINE; CLOMIPRAMINE; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; LEVOMEPROMAZINE; LITHIUM; NEUROLEPTIC AGENT; PHENYTOIN; PSYCHOTROPIC AGENT; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZOTEPINE;

ADULT; AGED; ARTICLE; BRADYCARDIA; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HEART RATE; HOLTER MONITORING; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RR INTERVAL;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; BRADYCARDIA; CROSS-SECTIONAL STUDIES; ELECTROCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; HEART RATE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PSYCHOTROPIC DRUGS; RETROSPECTIVE STUDIES; TORSADES DE POINTES;

EID: 5144219993     PISSN: 00220736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jelectrocard.2004.07.001     Document Type: Article

References (22)

1. Ray W.A., Meredith S., Thapa P.B., Meador K.G., et al. Antipsychotics and the risk of sudden death. Arch Gen Psychiatry. 58:2001;1161
2. Hennessey S., Bilker W.B., Knauss J.S., et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs cohort study using administrative data. BMJ. 325:2002;1070
3. Glassman A.H., Bigger J.H. Jr. Antipsychotic drugs Prolonged QTc interval, torsades de pointes, and sudden death. Am J Psychiatry. 158:2001;1774
4. Mehtonen O.-P., Aranko K., Mälkonen L., et al. A survey of 49 cases of sudden death associated with the use of antipsychotic or antidepressant drugs. Acta Psychiatr Scand. 84:1991;58
5. Risch S.G., Groom G.P., Janowsky D.S. Interface of psychopharmacology and cardiology-Part one. J Clin Psychiatry. 42:1981;23
6. Risch S.G., Groom G.P., Janowsky D.S. Interface of psychopharmacology and cardiology-Part two. J Clin Psychiatry. 42:1981;47
7. Marshall J.B., Forker A.D. Cardiovascular effects of tricyclic antidepressant drugs: Therapeutic usage, overdose, and management of complications. Am Heart J. 103:1982;401
8. + current activation in guinea pig ventricular myocytes. Circ Res. 74:1994;687
9. Teschemacher A.G., Seward E.P., Hancox J.C., et al. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyrine. Br J Pharmacol. 128:1999;479
10. Kemper A.J., Dunlap R., Pietro D.A. Thioridazine-induced torsade de pointes Successful therapy with isoproterenol. JAMA. 249:1983;2931
11. Hermann H.C., Kaplan L.M., Bierer B.E. Q-T prolongation and torsades de pointes ventricular tachycardia produced by the tetracyclic antidepressant agent maprotiline. Am J Cardiol. 51:1983;904
12. Strasberg B., Coelho A., Welch W., et al. Doxepin induced torsade de pointes. Pacing Clinic Electrophysiol. 5:1982;873
13. Garson A. How to measure the QT Interval-What is normal. Am J Cardiol. 72:1993;14B
14. Funck-Brentano C., Jaillon P. Rate-corrected QT interval techniques and limitations. Am J Cardiol. 72:1993;17B
15. Sadanaga T., Ogawa S., Okada Y., et al. Clinical evaluation of the use-dependent QRS prolongation and the reverse use-dependent QT prolongation of class I and class III antiarrhythmic agents and their value in predicting efficacy. Am Heart J. 126:1993;114
16. Hondeghem L.M., Snyders D.J. Class III antiarrhythmic agents have a lot of potentials but a long way to go Reduced effectiveness and dangers of reverse use dependence. Circulation. 81:1990;686
17. Reilly J.G., Ayis S.A., Jones S.J., et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 355:2000;1048
18. Rey M.-J., Scultz P., Costa C., et al. Guidelines for the dosage of neuroleptics I Chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol. 4:1989;95
19. Atkins M., Burgess A., Bottomley C., et al. Chlorpromazine equivalents A consensus opinion for both clinical and research applications. Psychiatr Bull. 21:1997;224
20. Lepeschkin E., Surawicz B. The measurement of the Q-T interval of the electrocardiogram. Circulation. 6:1952;378
21. Warner J.P., Barnes T.R.E., Henry J.A. Electrocardiographic changes in patients receiving neuroleptic medication. Acta Psychiatr Scand. 93:1996;311
22. Brown C.S., Farmer R.G., Soberman J.E., et al. Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. Clin Pharmacokinet. 43:2004;33